Vaginal dysbiosis increases risk of preterm fetal membrane rupture, neonatal sepsis and is exacerbated by erythromycin.

Richard G Brown, Julian R Marchesi, Yun S Lee, Ann Smith, Benjamin Lehne, Lindsay M Kindinger, Vasso Terzidou, Elaine Holmes, Jeremy K Nicholson, Phillip R Bennett, David A MacIntyre

Journal: BMC medicine 2018;16(1):9

PMID: 29361936

Plain Language Summary

plain language summary logo

Preterm premature rupture of the membranes (PPROM) is a pregnancy complication in which the amniotic sac ruptures before week 37 of the pregnancy, leading to an increased risk of infection and premature birth. Women who experience PPROM are usually given antibiotics to help prevent infections which, left untreated, could endanger their babies’ lives. It is thought that disturbances in the mum’s vaginal bacteria may be related to the risk of PPROM. In this study, researchers examined the vaginal bacteria of women with PPROM, before and after antibiotic treatment. A total of 250 pregnant women who had been identified as at risk of a premature birth were included in the study. Disturbance of the normal vaginal bacteria, characterised by low levels of Lactobacillus, was present in a third of women who went on to develop PPROM. This disturbance of the normal vaginal bacteria was made worse by antibiotic treatment particularly in women initially colonised by Lactobacillus spp. Lower levels of Lactobacillus and increased abundance of Sneathia spp. were associated with an increased likelihood of funisitis (inflammation of the umbilical cord) and sepsis in the newborn. The authors concluded that the composition of the vaginal microbiota is a risk factor for PPROM and is associated with unfavourable short-term outcomes for the mother and newborn. This highlights vaginal microbiota as a potentially modifiable risk factor for PPROM and they suggest that the routine use of antibiotics such as erythromycin for PPROM should be re-examined.

Abstract

BACKGROUND

Preterm prelabour rupture of the fetal membranes (PPROM) precedes 30% of preterm births and is a risk factor for early onset neonatal sepsis. As PPROM is strongly associated with ascending vaginal infection, prophylactic antibiotics are widely used. The evolution of vaginal microbiota compositions associated with PPROM and the impact of antibiotics on bacterial compositions are unknown.

METHODS

We prospectively assessed vaginal microbiota prior to and following PPROM using MiSeq-based sequencing of 16S rRNA gene amplicons and examined the impact of erythromycin prophylaxis on bacterial load and community structures.

RESULTS

In contrast to pregnancies delivering at term, vaginal dysbiosis characterised by Lactobacillus spp. depletion was present prior to the rupture of fetal membranes in approximately a third of cases (0% vs. 27%, P = 0.026) and persisted following membrane rupture (31%, P = 0.005). Vaginal dysbiosis was exacerbated by erythromycin treatment (47%, P = 0.00009) particularly in women initially colonised by Lactobacillus spp. Lactobacillus depletion and increased relative abundance of Sneathia spp. were associated with subsequent funisitis and early onset neonatal sepsis.

CONCLUSIONS

Our data show that vaginal microbiota composition is a risk factor for subsequent PPROM and is associated with adverse short-term maternal and neonatal outcomes. This highlights vaginal microbiota as a potentially modifiable antenatal risk factor for PPROM and suggests that routine use of erythromycin for PPROM be re-examined.

Address: Imperial College Parturition Research Group, Division of the Institute of Reproductive and Developmental Biology, Imperial College London, London, W12 0NN, UK.; Centre for Digestive and Gut Health, Imperial College London, London, W2 1NY, UK.; School of Biosciences, Cardiff University, Cardiff, CF103AX, UK.; School of Biosciences, Cardiff University, Cardiff, CF103AX, UK.; Department of Epidemiology & Biostatistics, Medicine, Imperial College London, London, W2 1PG, UK.; Imperial College Parturition Research Group, Division of the Institute of Reproductive and Developmental Biology, Imperial College London, London, W12 0NN, UK.; Chelsea & Westminster Hospital, Imperial College Healthcare NHS Trust, London, SW10 9NH, UK.; Centre for Digestive and Gut Health, Imperial College London, London, W2 1NY, UK.; Division of Computational Systems Medicine, Department of Surgery and Cancer, Imperial College London, London, SW7 2AZ, UK.; Imperial College Parturition Research Group, Division of the Institute of Reproductive and Developmental Biology, Imperial College London, London, W12 0NN, UK.; Queen Charlotte's Hospital, Imperial College Healthcare NHS Trust, London, W12 0HS, UK.; Imperial College Parturition Research Group, Division of the Institute of Reproductive and Developmental Biology, Imperial College London, London, W12 0NN, UK. [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.